cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1748Research ArticleОБЗОРЫREVIEWSОсобенности фармакологического воздействия на симпатический тонус и частоту сердечных сокращений при сердечно-сосудистых заболеванияхPharmacological effects оп sympathetic tonus and heart rate in cardiovascular diseaseЗагидуллинН. Ш.ZagidullinN. Sh.

Ассистент кафедры пропедевтики внутренних болезней с курсом физиотерапии.

Уфа.

Тел.: (3472) 37-71-14

Ufa.

nau36@ufanet.ruЗагидуллинШ. 3.ZagidullinSh. Z.

Заведующий кафедрой.

Уфа. 

Ufa.

Башкирский государственный медицинский университет РосздраваBashkir State Medical University200920042009828994Copyright © Загидуллин Н.Ш., Загидуллин Ш.3., 20092009Загидуллин Н.Ш., Загидуллин Ш.3.Zagidullin N.S., Zagidullin S.Z.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1748

Одним из основных направлений в лечении артериальной гипертензии (АГ) и ишемической болезни сердца (ИБС) в последнее время служит снижение активности симпатической нервной системы и одного из ее важнейших маркеров - частоты сердечных сокращений (ЧСС), которая является независимым фактором риска развития сердечно-сосудистых осложнений. В настоящее время выделяют 3 наиболее распространенные группы лекарственных препаратов, модулирующих симпатическую активность: β-адреноблокаторы (β-АБ), ингибиторы Ifканала и антагонисты кальция, преимущественно дигидропиридинового ряда (верапамил СР). Верапамил СР, в отличие от β-АБ, умеренно снижает ЧСС и гиперсимпатикотонию, одновременно обладая высокой антигипертензивной, антиангинальной активностью, и минимальным количеством побочных эффектов, является препаратом выбора как при AГ, так и ИБС. 

Recently, оnе of the leading approaches in the management of arterial hypertension (АН) and coronary heart disease (CHD) is reduction of sympathetic activity and оnе of its markers, heart rate (HR). HR is known as an independent predictor of cardiovascular risk. At present, there are three main groups of the medications modulating sympathetic activity: beta-adrenoblockers (ВАВ), If channel inhibitors, and calcium antagonists, mostly dihydropyridine-type ones (verapamil SR). In contrast to ВАВ, verapamil SR combines moderate reduction in HR and sympathetic tonus with high antihypertensive and anti-anginal activity and minimal adverse effects. Therefore, verapamil SR is а medication of choice in АН and CHD treatment. 

симпатическая нервная системачастота сердечных сокращенийрегуляция ритма сердцасердечно-сосудистая смертностьфармакотерапияsympathetic autonomous systemheart гаtеheart rate regulationcardiovascular mortalitypharmacotherapyReferencesMesserli FH, Grossman Е, Goldbourt U. Аге beta-blockers efficacious as first-line therapy for hypertension in the elderly? А systematic review. JАМА 1998; 279: 1903- 7.Messerli FH, Grossman Е, Goldbourt U. Аге beta-blockers efficacious as first-line therapy for hypertension in the elderly? А systematic review. JАМА 1998; 279: 1903- 7.Rehnqvist N, Hjemdahl Р, Billing Е, et al. Effects of metoprolol vs. verapamil in patients with stable angina pectoris. The Angina Pectoris Study in Stockholm (APSIS). Eur Heart J 1996; 17: 76-81.Rehnqvist N, Hjemdahl Р, Billing Е, et al. Effects of metoprolol vs. verapamil in patients with stable angina pectoris. The Angina Pectoris Study in Stockholm (APSIS). Eur Heart J 1996; 17: 76-81.Dardie HJ, Ford I, Fox КМ. Total Ischemic Burden European Trial (ТIВЕТ). Effects of ischemia and treatment with atenolol, nifedipine SR and their combinations оn outcome in patients with chronic stable angina. The TIВЕТ Study Group. Eur HeartJ 1996; 17: 104-12.Dardie HJ, Ford I, Fox КМ. Total Ischemic Burden European Trial (ТIВЕТ). Effects of ischemia and treatment with atenolol, nifedipine SR and their combinations оn outcome in patients with chronic stable angina. The TIВЕТ Study Group. Eur HeartJ 1996; 17: 104-12.Мо R, Nordrehaug J, Omvick Р, Lund-Johansen Р. The Berg blооd pressure study: prehypertensive changes in cardiac structure and function in offspring of hypertensive families. Вlood Pressure 1995; 4: 1017-27.Мо R, Nordrehaug J, Omvick Р, Lund-Johansen Р. The Berg blооd pressure study: prehypertensive changes in cardiac structure and function in offspring of hypertensive families. Вlood Pressure 1995; 4: 1017-27.Cohn JN, Levine ТВ, Olivari МТ, et al. Plasma norepinephrine as а guide to prognosis in patients with chronic congestive heart failure. N EnglJ Med 1984; 311: 819-23.Cohn JN, Levine ТВ, Olivari МТ, et al. Plasma norepinephrine as а guide to prognosis in patients with chronic congestive heart failure. N EnglJ Med 1984; 311: 819-23.Farinaro Е, Della Valle Е, Ferrantino G. Plasma lipids and cardio­vascular risk: lesions in the community. Ann Ital Med Int 1995: 10(Suppl.): 31-4.Farinaro Е, Della Valle Е, Ferrantino G. Plasma lipids and cardio­vascular risk: lesions in the community. Ann Ital Med Int 1995: 10(Suppl.): 31-4.Kolloch R, Legler U, Champion А, et al. Impact of resting heart rate оn outcomes in hypertensive patients with coronary artery disease: findings from the lntemational Verapamil-SR/trandolapril STudy (INVEST). Eur HeartJ 2008; 29: 1327-34.Kolloch R, Legler U, Champion А, et al. Impact of resting heart rate оn outcomes in hypertensive patients with coronary artery disease: findings from the lntemational Verapamil-SR/trandolapril STudy (INVEST). Eur HeartJ 2008; 29: 1327-34.Shell W, Sobel В. Deleterious effects of increased heart rate оn infarctsize in the conscious dog. Ат J Cardiol 1973; 31: 474-9.Shell W, Sobel В. Deleterious effects of increased heart rate оn infarctsize in the conscious dog. Ат J Cardiol 1973; 31: 474-9.Levy RL, White PD, Strod WD, Hillman СС. Transient tachycardia: prognostic significance alone and in association with transient hypertension. JАМА 1945; 129: 585-8.Levy RL, White PD, Strod WD, Hillman СС. Transient tachycardia: prognostic significance alone and in association with transient hypertension. JАМА 1945; 129: 585-8.Perski А, Hamsten А, Lindvall К, Theorel Т. Heart rate correlates with severity of coronary atherosclerosis in young postinfarction patients. Ат Heart J 1988; 116: 1369- 73.Perski А, Hamsten А, Lindvall К, Theorel Т. Heart rate correlates with severity of coronary atherosclerosis in young postinfarction patients. Ат Heart J 1988; 116: 1369- 73.Heidland UE, Stauer ВЕ. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque dysruption. Circulation 2001; 104: 1477-82.Heidland UE, Stauer ВЕ. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque dysruption. Circulation 2001; 104: 1477-82.Шальнова СА., Деев АД., Оrанов P.Г. и др. Частота пульса и смертность от сердечно-сосудистых заболеваний у российских мужчин и женщин. Результаты эrmдемиолоrическоrо исследования. Кардиология 2005; 10: 45-50.Шальнова СА., Деев АД., Оrанов P.Г. и др. Частота пульса и смертность от сердечно-сосудистых заболеваний у российских мужчин и женщин. Результаты эrmдемиолоrическоrо исследования. Кардиология 2005; 10: 45-50.Gillum R, Makus D, Feldman J. Pulse rate, coronary heart disease and death: The NНANES I epidemiological follow-up study. Ат HeartJ 1991; 121: 172-7.Gillum R, Makus D, Feldman J. Pulse rate, coronary heart disease and death: The NНANES I epidemiological follow-up study. Ат HeartJ 1991; 121: 172-7.Gilman М, Karmel W, Belanger А, D'Agostino R. Influence of heart rate on mortality among persons with hypertension The Framingham study. Ат Н J 1993; 125: 1148-54.Gilman М, Karmel W, Belanger А, D'Agostino R. Influence of heart rate on mortality among persons with hypertension The Framingham study. Ат Н J 1993; 125: 1148-54.Palatini Р. Heart rate as а risk factor for atherosclerosis and cardiovascular mortality: the effect of antihypertensive drugs. Drugs 1999; 57: 713-24.Palatini Р. Heart rate as а risk factor for atherosclerosis and cardiovascular mortality: the effect of antihypertensive drugs. Drugs 1999; 57: 713-24.CIВIS II lnvestigators and committers. The cardiac insufficiency bisoprololstudy II (CIВIS II): arandomized trial. Lancet 1999; 353: 9-13.CIВIS II lnvestigators and committers. The cardiac insufficiency bisoprololstudy II (CIВIS II): arandomized trial. Lancet 1999; 353: 9-13.Fox К, Ford I, Steg PG, et al. Heart rate as а prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUТIFUL): а subgroup analysis of а randomized controlled trial. Lancet 2008; 372: 817-21.Fox К, Ford I, Steg PG, et al. Heart rate as а prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUТIFUL): а subgroup analysis of а randomized controlled trial. Lancet 2008; 372: 817-21.Benetos А, Rudnichi А, Thomas F, et al. Influence of heart rate on mortality in а French population: role of age, gender and blооd pressure. Hypertension 1999; 33: 44-52.Benetos А, Rudnichi А, Thomas F, et al. Influence of heart rate on mortality in а French population: role of age, gender and blооd pressure. Hypertension 1999; 33: 44-52.DiFrancesco D. Pacemaker mechanisms in cardiac tissue. Ann Rev Physiol 1993; 55: 455-72.DiFrancesco D. Pacemaker mechanisms in cardiac tissue. Ann Rev Physiol 1993; 55: 455-72.Fox К, Garcia МА, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1241-381.Fox К, Garcia МА, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1241-381.Boden WE, Vray М, Eschwege Е, et al. Heart rate-lowering and -regulating effects of once-daily sustained-release diltiazem. Clin Cardiol 2001; 24(1): 73-9.Boden WE, Vray М, Eschwege Е, et al. Heart rate-lowering and -regulating effects of once-daily sustained-release diltiazem. Clin Cardiol 2001; 24(1): 73-9.Lefrandt JD, van Roon АМ, van Gessel, et al. Improved Short­Term Вlood Pressure Control bу treatment with calcium antagonists in patients with mild or moderate hypertension. J Hypertens 1999; l 7(Suppl.3).Lefrandt JD, van Roon АМ, van Gessel, et al. Improved Short­Term Вlood Pressure Control bу treatment with calcium antagonists in patients with mild or moderate hypertension. J Hypertens 1999; l 7(Suppl.3).Novo S, Alaimo G, Abrignani MG, et al. Noninvasive blооd pressure monitoring evaluation of verapamil slow-release 240-mg anti­hypertensive effectiveness. J Cardiovasc Pharmac 1989; 13(Suppl. 4): S38-41.Novo S, Alaimo G, Abrignani MG, et al. Noninvasive blооd pressure monitoring evaluation of verapamil slow-release 240-mg anti­hypertensive effectiveness. J Cardiovasc Pharmac 1989; 13(Suppl. 4): S38-41.Pepine CJ, Handberg Е, Cooper-De-Hoff R, et al. А Calcium Antagonist vs Non-Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease. The lntemational Verapamil-Trandolapril Study (INVEST): А Randomized Controlled Trial. JАМА 2003; 290(21): 2805-16.Pepine CJ, Handberg Е, Cooper-De-Hoff R, et al. А Calcium Antagonist vs Non-Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease. The lntemational Verapamil-Trandolapril Study (INVEST): А Randomized Controlled Trial. JАМА 2003; 290(21): 2805-16.de Champlain J, Yacine А, Le Вlanc R, et al. Effects oftrandolapril on the sympathetic tone and reactivity in systemic hypertension. J Hypertens 1994; 73(10): 18С-25.de Champlain J, Yacine А, Le Вlanc R, et al. Effects oftrandolapril on the sympathetic tone and reactivity in systemic hypertension. J Hypertens 1994; 73(10): 18С-25.Messerli F, Frishman WН, Elliott WJ, et al. Antihypertensive properties of а high-dose combination of trandolapril and verapamil-SR. Вlood Press Suppl 2007; 1: 6-9.Messerli F, Frishman WН, Elliott WJ, et al. Antihypertensive properties of а high-dose combination of trandolapril and verapamil-SR. Вlood Press Suppl 2007; 1: 6-9.Bakris G, Molitch М, Hewkin М, et al. Difference in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Саге 2006; 12: 2592- 7.Bakris G, Molitch М, Hewkin М, et al. Difference in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Саге 2006; 12: 2592- 7.Bakris GL, Williams В. Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? J Hypertens 1995; 13(Suppl. 2): S95-101.Bakris GL, Williams В. Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? J Hypertens 1995; 13(Suppl. 2): S95-101.Bakris G, Molitch М, Zhou Q, et al. Reversal of Diuretic­ Associated Impaired Glucose Tolerance and New-Onset Diabetes: Results of the STAR-LET Study. J Cardiometab Syndr 2008; 3: 18-25.Bakris G, Molitch М, Zhou Q, et al. Reversal of Diuretic­ Associated Impaired Glucose Tolerance and New-Onset Diabetes: Results of the STAR-LET Study. J Cardiometab Syndr 2008; 3: 18-25.Tardif JC, Ford I, Tendera М, et al. Efficacy of ivabradine, а new selective 1 (f) inhiЬitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529-36.Tardif JC, Ford I, Tendera М, et al. Efficacy of ivabradine, а new selective 1 (f) inhiЬitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529-36.Borer J, Fox К, Jaillon Р. Antianginal and Antiischemic Effects of Ivabradine, anlr lnhibitor, in StableAngina. ARandomized, Double­Blind, Multicentered, Placebo-Controlled Trial. Circulation 2003; 107: 817-23.Borer J, Fox К, Jaillon Р. Antianginal and Antiischemic Effects of Ivabradine, anlr lnhibitor, in StableAngina. ARandomized, Double­Blind, Multicentered, Placebo-Controlled Trial. Circulation 2003; 107: 817-23.Fox К, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUТIFUL): а randomised, double-blind, placebo-controlled trial. Lancet 2008; 372(9641): 779-80.Fox К, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUТIFUL): а randomised, double-blind, placebo-controlled trial. Lancet 2008; 372(9641): 779-80.Sripal Bangalore, SaЬrina SawhneY, Franz H.Messerli. Relation of Beta- Вlocker- lnduced Heart Rate Lowering and Cardioprotection in Hypertension. Jornal of the American College of Cardioily; vol.52,No18, 2008.Sripal Bangalore, SaЬrina SawhneY, Franz H.Messerli. Relation of Beta- Вlocker- lnduced Heart Rate Lowering and Cardioprotection in Hypertension. Jornal of the American College of Cardioily; vol.52,No18, 2008.

The authors declare that there are no conflicts of interest present.